The alliance is expected to bring together the high quality scientific capabilities of Sundia and HD BioSciences with NovaSecta’s extensive client base and unique understanding of European mid-sized pharmaceutical and biotech companies.
Xiaochuan Wang, Sundia Meditech’s founder and CEO and Xuehai Tan, founder and CEO of HD BioSciences, said: “We believe that by extending our alliance to include NovaSecta, we will bring significant benefits to European customers, so we look forward to working with NovaSecta and more European clients.”